Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.

A Winnipeg couple has temporarily relocated to Memphis, Tennessee, in search of lifesaving treatment for their 3-year-old son ...

One main goal of anti-cancer therapies is to kill tumor cells without affecting the surrounding normal cells. Therefore, many ...

Promising Cell Therapy Offers Hope for Relapsed or ... team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the ...

Ziftomenib’s FDA application for relapsed/refractory NPM1-mutant acute myeloid leukemia is supported by data from the ...

The first patient with relapsed or refractory acute myeloid leukemia has been dosed with Annamycin plus Cytarabine in the ...

Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to ...

A seven-year-old boy holds a sign with four words that his family and the community have been waiting to hear: “I am cancer ...

Exicure, Inc. (Nasdaq: XCUR) today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. Exicure, Inc. ("Exicure") is planning for a clinical trial in Acute Myeloid ...

Syndax has a strong cash position and a significant market opportunity with Revuforj and Niktimvo. Check out my ...